Regeneron (NASDAQ:REGN) and Sanofi (NASDAQ:SNY) have started a clinical trial to see if Kevzara -- a drug that has been approved by the Food and Drug Administration as an arthritis treatment -- works on COVID-19. The companies hope that the monoclonal antibody will reduce fever and the need for supplemental oxygen in patients with severe cases of the illness. 

Because they are working with a drug that has already been approved, the companies can skip the phase 1 trial stage, in which a drug's safety profile is established. Kevzara already has a proven safety record in patients. The only question is whether it helps against COVID-19. 

Doctors in Hazmat suits treat sick patient

Image source: Getty Images

Right now, there are no approved drugs for COVID-19. In China, medical authorities have been trying drugs approved for other indications to treat patients with the disease. One is Actemra, an arthritis drug from Roche (OTC:RHHBY). Actemra and Kevzara are highly similar pharmaceuticals -- interleukin 6 (IL-6) inhibitors approved as treatments for rheumatoid arthritis. 

The reason that researchers view IL-6 inhibitors as a promising avenue here is that the most severe cases of COVID-19 feature a dangerous and excessive immune reaction called a cytokine storm. Chinese health authorities have listed an elevated IL-6 condition as a sign of the disease getting worse. As inhibitors of IL-6, both Actemra and Kevzara might work to ease those patients' symptoms. 

In one small trial in China, medical authorities found that an IL-6 inhibitor rapidly reduced the fevers of COVID-19 patients. And 75% of patients had a reduced need for supplemental oxygen after taking the drug. 

Kevzara will be tested in approximately 400 patients at 16 sites around the country, starting in New York.   

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.